The role of NADPH oxidase in both the early and the late phase of ischaemia, with or without reperfusion, is yet to be explored with potent, specific inhibitors, but such studies may well offer opportunities for therapeutic intervention in the progression of brain damage following stroke, or in the regeneration phase after stroke. This evidence concerns the gene FMO5 and Stroke.